Oricell Therapeutics

原启生物 - 成为创新驱动的全球领先,肿瘤免疫治疗新药的创制者

Shanghai, China · Founded 2019 · $364.0M raised

Headquarters
Shanghai
Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$364.0M
Last Round
$110.0M Venture RoundApr 2026
Rounds
5

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Oricell Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative and affordable immunotherapies for hematological malignancies and solid tumors. Its lead program, OriCAR-017, is a GPRC5D-targeting autologous CAR-T therapy for relapsed/refractory multiple myeloma with FDA and NMPA IND approvals. Oricell also advances Ori-C101, a GPC3-targeting CAR-T for hepatocellular carcinoma, leveraging its proprietary OriAb antibody library platform.

Summary

Oricell Therapeutics is an Oncology company based in Shanghai, China, founded in 2019. It has raised $364.0M in total across 5 rounds, most recently a $110.0M Venture Round in Apr 2026. Investors include Qiming VP, Vivo Capital and Beijing Medical and Health Care Industry Investment Fund.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundApr 2026
$110.0M

Sign up to see all 5 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

ImmunomedicsAcquired

Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...

Morris Plains, United States201–500Biotech, Oncology
Private EquityTotal funding$459.0MMay 2020
ArcellxAcquired

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...

Redwood City, United States51–200Biotech, Healthcare
SeedTotal funding$375.0MJan 2024
PIONYR ImmunotherapeuticsAcquired

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenviron...

South San Francisco, United States51–200Biotech, Healthcare
Corporate RoundTotal funding$355.0MJun 2020
Bicara TherapeuticsIPO

Clinical-stage biopharma developing dual-action biologics that combine targeted therapy and immun...

Cambridge, United States51–200Biotech, Healthcare
Series CTotal funding$313.0MDec 2023
Adicet Bio

Menlo Park, CA & Boston, MA

Redwood City, United States51–200Biotech, Healthcare
Venture RoundTotal funding$211.0MOct 2025
Callio Therapeutics

Callio Therapeutics is a clinical-stage biotech developing dual-payload antibody-drug conjugates,...

Seattle, United States1–10Biotech, Oncology
Series ATotal funding$187.0MMar 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Oricell Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/oricell-therapeutics"><img src="https://indexed.vc/api/badge/company/oricell-therapeutics" alt="Oricell Therapeutics on Indexed.vc" width="260" height="76" /></a>